Log inTry free

C4 Therapeutics (CCCC) stock

Market cap $386M

$2.99
+1.36%

Market closed. Prices as of Monday's close.

Quality Score
-3
Poor
In its industry
#196of 300
Biotech

CCCC's Quality Score rose 1 point on Mon, Oct 5, to -3. Its volume went quiet (2 chart checks started).

NextQ1 2027“…in late-line multiple myeloma (MM) treatment is on track to complete enrollment in the first quarter of 2027…”Trial start · 8-K, Aug 11
Cash$300M, about 14 quarters (3.5 years) at the last year's spendingOn Jun 30

Follow CCCC's trial news. Pro members can get an alert when C4 Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when CCCC files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Cash$300M, about 14 quarters (3.5 years) at the last year's spendingOn Jun 30

What's next for CCCC, and how long its cash lasts

From C4 Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Q1 2027“…Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone in late-line multiple myeloma (MM) treatment is on track to complete enrollment in the first quarter of 2027.”Trial start · 8-K, Aug 11

What it means: when a trial begins, or reaches the stage the company named.

Lead program
Cemsidomide · Multiple Myeloma · Phase 2
Its trial
MOMENTUMPhase 2 · Recruiting · 100 people · main data estimated Mar 2030 · NCT07284758

2 more trials, 2 more milestones and 41 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 14 quarters

$300M in cash and investments (the company's own count), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Nov 21, 2025)
  • At-the-market share sales program (424B5, filed Dec 10, 2025)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

Chief Medical Officer Leonard Reyno sold 10,000 shares on Jan 16.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Andrew Hirsch buys or sells

For Pro members: every trade, and Andrew Hirsch’s 10 filings and quotes.

Get an optional alert when CCCC files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 113 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why it's down

Down 29% in 3 months, 19% under its 50-day average.

Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.

−2Long-term trend below a falling 200-day average, down over two years

4 more things pulling CCCC's score down, for Pro members

What's next

Expected to report Thu Nov 5, before the open

After its last 4 reports it closed +1.9% on average, higher 3 of 4 times.

What would turn CCCC's score around: 9 things, for Pro members

Alert me when CCCC's Quality Score turns up

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on CCCC and every other stock.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

CCCC has 3 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on CCCC, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

  • RSI 1435.7

    Above 30, below 50.

  • MACD (12, 26, 9)Below signal

    Crossed below its signal line 25 sessions ago.

  • 50-day average$3.62

    The price is 17.4% below it.

  • 200-day average$3.12

    The price is 4.2% below it. The 50-day is above the 200-day, since Mar 10.

  • ADX 1422.4

    Under 25, with +DI below -DI.

  • Support$2.88

    Swing low from Sep 24, 3.7% below the price.

  • Resistance$3.02

    Swing high from Apr 6, 1.0% above the price.

  • Bollinger Bands (20, 2)Inside

    The bands run from $2.89 to $3.65.

  • Volume0.7x

    Against its 20-day average, for the time of day.

How CCCC ranks in Biotech

CCCC is #196 of 300 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

When does CCCC report earnings, and what happens after?

Expected to report Thu Nov 5, before the open (in 30 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Aug 11, 2026Before open+6.1%+6.9%+17.8%
May 12, 2026Before open-2.8%0.0%+1.6%
Feb 26, 2026Before open+5.8%+0.4%+11.6%
Nov 6, 2025Before open-0.8%+0.4%+4.6%

The gap is the next open against the close before the report; the reaction is where that session closed. CCCC closed higher after 3 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

About C4 Therapeutics

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

104 employeesWatertown, MAc4therapeutics.com

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of CCCC's score, with the points and the reason
  • All 14 checks on CCCC and on all 3,243 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on CCCC
See all 14 checks on CCCCSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.